GlassScriptPhysician profile
Kevin F Clancy
NPI 1346245149
$4,367.86
in general payments reported to CMS, 2019-2025
36 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $696 · 2021: $721 · 2022: $802 · 2023: $589 · 2024: $425 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,337.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $649.08 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $348.40 | 2019-2024 | Farxiga |
| Boston Scientific Corporation | $323.34 | 2019-2025 | Watchman Flx, Patientcare Link, Bodyguardian |
| Abbott Laboratories | $297.40 | 2019-2024 | Aveir, Freestyle Libre 3 |
| Pfizer INC. | $282.63 | 2019-2024 | |
| Medtronic, INC. | $267.10 | 2021 | |
| Philips North America LLC | $263.86 | 2022-2025 | (5044) Mcot, Mcot, Event |
| Novo Nordisk INC | $237.51 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic Vascular, INC. | $231.06 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $227.36 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $217.59 | 2020-2023 | |
| Cvrx, INC. | $168.95 | 2023-2025 | Barostim Neo System |
| Astellas Pharma US INC | $104.53 | 2020-2021 | |
| Endologix LLC | $99.05 | 2020 | |
| Merck Sharp & Dohme LLC | $90.62 | 2021-2024 | Verquvo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.90 | 2019-2024 | Jardiance |
| Amgen INC. | $54.90 | 2019-2022 | |
| Irhythm Technologies, INC. | $45.20 | 2022 | |
| Lilly USA, LLC | $35.93 | 2024 | Zepbound |
| Corcept Therapeutics | $32.51 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $31.79 | 2025 | Shingrix, Arexvy |
| Biosense Webster, INC. | $30.20 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $29.60 | 2021-2023 | Arcalyst |
| Impulse Dynamics (USA) INC. | $27.53 | 2024 | Optimizer |
| Gilead Sciences, INC. | $26.82 | 2019 | |
| Edwards Lifesciences Corporation | $26.10 | 2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $20.44 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $20.07 | 2023 | Inpefa |
| Medicomp INC | $18.23 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.84 | 2022 | |
| Daiichi Sankyo INC. | $14.70 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $14.69 | 2022 | |
| Amarin Pharma, INC. | $13.90 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Clancy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.